News

Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.

Disney’s next quarterly results are expected to be released Wednesday morning, with traders expecting a big move from the entertainment giant’s stock.

DAVE heads into Q2 earnings with beat potential as ExtraCash demand, fee changes and credit gains support growth, though valuation and spending are likely to have tempered the setup.

Pinterest is scheduled to report second-quarter financial results after the stock market closes on Tuesday.

BR's fiscal fourth-quarter earnings and revenues top estimates as recurring revenues, closed sales and GTO profitability strengthen.

APO's Q2 results are affected by higher expenses as adjusted net income misses estimates. Higher AUM and revenue growth provide support.

Wix.com's (WIX) Q2 results marked a "step forward" as the company maintained its full-year outlook a

Nokia Oyj (HLSE:NOKIA) stock is back in focus after the company reported second quarter 2026 results and issued third quarter guidance that assumes a 3% to 7% quarter on quarter rise in net sales. See our latest analysis for Nokia Oyj. At a share price of €8.10, Nokia Oyj has seen the 30 day share price return fall 27.48% and the 90 day share price return fall 28.60%. However, the year to date share price return is 46.63% and the 1 year total shareholder return is 134.96%, which suggests that...

Leidos Holdings (LDOS) reported second quarter 2026 results and updated its outlook, giving investors fresh data on revenue, earnings and guidance after a run of new contract wins and capital returns. See our latest analysis for Leidos Holdings. The recent earnings beat, higher full year guidance and a series of defense and AI related contract wins have helped Leidos Holdings shares post a 9.1% 30 day share price return. However, year to date the share price is down 35.3% and the 1 year total...

Disney (DIS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

TDG posts stronger-than-expected Q3 results, fueled by broad organic sales growth, while raising its fiscal 2026 outlook on solid operating momentum.

ET's second-quarter earnings beat estimates as record NGL volumes and stronger crude activity drive growth, prompting a higher 2026 EBITDA outlook.

Maplebear heads into Q2 earnings with a positive Earnings ESP, backed by marketplace, enterprise and ad growth despite cautious consumer spending.

All three major US stock indexes were up in late-morning trading Tuesday, as investors grew more opt

IQM Quantum Computers (NASDAQ:IQMX) reported its first results as a public company, outlining a growing order backlog, a second-half-weighted revenue outlook and continued investment in superconducting quantum systems for high-performance computing environments. The company began trading on the Nas

IPG Photonics (NASDAQ:IPGP) reported second-quarter 2026 revenue of $279 million, up 11% from a year earlier and representing its third consecutive quarter of double-digit year-over-year sales growth. Revenue exceeded the midpoint of the company’s guidance, while bookings improved and book-to-bill r

Hut 8 (NASDAQ:HUT) reported second-quarter 2026 revenue growth and improved adjusted EBITDA as its compute operations expanded, while management highlighted progress on its AI data center development projects and project-level financing strategy. Revenue rose approximately 81% year over year to $74

Hotchkis & Wiley, an investment management company, released its second-quarter 2026 investor letter for the “Hotchkis & Wiley Mid-Cap Value Fund.” A copy of the letter can be downloaded here. Equity markets posted strong returns in the second quarter of 2026, with the Russell Midcap Index rising 13.8% and the Russell Midcap Value Index returning 13.4%, […]

Zebra Technologies tops second-quarter earnings and revenue estimates as broad-based growth and acquisitions fuel sales, prompting higher full-year 2026 guidance.

Autodesk currently trades at $246.30 per share and has shown little upside over the past six months, posting a small loss of 2.6%. The stock also fell short of the S&P 500’s 7.1% gain during that period.

Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

POWL's fiscal Q3 earnings and revenues miss estimates, even as record orders and a $2.4 billion backlog strengthen its outlook.

EME's record backlog, AI infrastructure demand and acquisitions are strengthening growth, as it lifts its 2026 revenue and earnings outlook.

Space stocks are surging ahead of SpaceX's first-ever public earnings report, but with prediction markets flagging a 70% chance of a miss and a 911-million-share lockup expiry days away, traders face a tense setup that could cut either way.

Fidelity National tops Q2 EPS estimates as Banking Solutions fuels growth and margins improve, but the company lowers its full-year revenue and earnings outlook.

Block heads into the Q2 earnings release with 20% gross profit growth targeted, Cash App and Square momentum, and bitcoin volatility shaping the outlook.

Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

BWXT raises its 2026 outlook as stronger operations support higher guidance, while a medical divestiture and PCG deal sharpen its nuclear focus.

PHIN misses Q2 earnings estimates despite higher sales as employee costs and product mix weigh on margins.